Handelsbanken Fonder’s Catalyst Pharmaceutical CPRX Stock Holding History

Handelsbanken Fonder’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Buy	42,277 +2,100	+5%	+$62K	﹤0.01%	1003
2026 Q1	$995K	Hold	40,177	–	–	﹤0.01%	1046
2025 Q4	$938K	Buy	40,177 +8,100	+25%	+$180K	﹤0.01%	1058
2025 Q3	$632K	Hold	32,077	–	–	﹤0.01%	1185
2025 Q2	$696K	Sell	32,077 -3,400	-10%	-$80.3K	﹤0.01%	1109
2025 Q1	$860K	Hold	35,477	–	–	﹤0.01%	999
2024 Q4	$740K	Buy	35,477 +1,000	+3%	+$21.5K	﹤0.01%	1125
2024 Q3	$685K	Buy	34,477 +5,500	+19%	+$102K	﹤0.01%	1104
2024 Q2	$449K	Buy	28,977 +3,700	+15%	+$57.6K	﹤0.01%	1205
2024 Q1	$403K	Hold	25,277	–	–	﹤0.01%	1264
2023 Q4	$425K	Sell	25,277 -2,600	-9%	-$35.5K	﹤0.01%	1224
2023 Q3	$326K	Buy	27,877 +13,377	+92%	+$179K	﹤0.01%	1274
2023 Q2	$195K	Buy	+14,500	New	+$209K	﹤0.01%	1496

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CIEC

Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

CWP

Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CNAM

Campbell Newman Asset Management Milwaukee, Wisconsin $1.35B AUM 38.87% 1-Year Est. Return

Handelsbanken Fonder's CPRX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Catalyst Pharmaceutical (CPRX) stake by 5.2% in Q2 2026, buying an estimated $62K and bringing the position to 42,277 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1003.

Handelsbanken Fonder first reported a position in CPRX in Q2 2023 and has held it in 13 quarters since. 101 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Handelsbanken Fonder held 42,277 shares of Catalyst Pharmaceutical worth $1.33M as of Q2 2026.
Handelsbanken Fonder bought 2,100 Catalyst Pharmaceutical shares in Q2 2026, an estimated $62K.
Catalyst Pharmaceutical made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1003 holding.
Handelsbanken Fonder first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
101 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.